Single intratumoral injections of a NanoZolid formulated STING agonist has been proven to achieve significant effects on tumor growth reduction and overall survival. These positive effects of the NanoZolid formulation with STING puts LIDDS in an exciting position in the immuno-oncology field having a technology to avoid frequent injections. The findings are now included in a patent application.
The NanoZolid technology has in aggressive tumor models shown to enable a controlled release of a STING agonist intratumorally. With the NanoZolid drug delivery technology, a single injection of a NanoZolid formulated STING agonist (NZ-STING) could replace required multiple injections and thereby provide a safer, more convenient and potentially more effective treatment. The NZ-STING efficacy has been demonstrated in several preclinical animal studies where a single injection has shown effects on tumor growth and overall survival.
It is very exciting that NanoZolid with STING agonist has shown so positive results. STING agonists are agents that must be administered directly into tumors on at least a weekly basis. This is a perfect match for LIDDS as the NanoZolid technology can provide pharma companies with a competitive advantage avoiding these frequent injections. It is also interesting that big pharma companies are actively competing to develop this novel class of agents and deals with STING agonists has been rocketing lately as a result of this, says Monica Wallter, CEO of LIDDS.
STING agonists are novel immunotherapy agents, seen as one of the most promising agents for the treatment of cancers and consequently these are being aggressively researched and pursued by leading Big Pharma companies. Several deals with potential values up to 2 billion USD have been made despite the early stages of this therapeutic area. This highlights the competitiveness of the field to develop new and more effective cancer treatments.
Immuno-oncology is the fastest growing area in oncology, forecasted to reaching a market size over 100 billion USD by 2022.
For more information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, firstname.lastname@example.org
LIDDS is required to disclose the information in this press release under the European Union’s Market Abuse Regulation and the Securities Market Act. The information was submitted through the agency of the aforementioned contact person for publication on 15 March 2018 at 08.30 CET.
LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid can be combined with both large and small pharmaceutical molecules. The company’s most advanced project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North. Redeye AB is a certified adviser to LIDDS. For more information, go to www.liddspharma.com.